FibroBiologics to Present at Bio-Europe 2025
FibroBiologics (Nasdaq: FBLG) announced that Founder and CEO Pete O’Heeron will present at Bio-Europe 2025 in Vienna, Austria, on November 4, 2025 at 4:15 p.m. CET.
The company said it will be available for one-on-one investor meetings during the conference (November 3–5, 2025) and that additional information is available via the company website or email at info@fibrobiologics.com. FibroBiologics focuses on therapeutics using fibroblasts and fibroblast-derived materials and holds 270+ patents issued and pending.
FibroBiologics (Nasdaq: FBLG) ha annunciato che il fondatore e CEO Pete O’Heeron parteciperà come relatore a Bio-Europe 2025 a Vienna, in Austria, il 4 novembre 2025 alle 16:15 CET.
L'azienda ha dichiarato che sarà disponibile per incontri one-on-one con investitori durante la conferenza (3-5 novembre 2025) e che ulteriori informazioni sono disponibili sul sito dell'azienda o via email all'indirizzo info@fibrobiologics.com. FibroBiologics si concentra su terapie che utilizzano fibroblasti e materiali derivati dai fibroblasti e detiene oltre 270 brevetti rilasciati e in attesa.
FibroBiologics (Nasdaq: FBLG) anunció que el fundador y CEO Pete O’Heeron presentará en Bio-Europe 2025 en Viena, Austria, el 4 de noviembre de 2025 a las 16:15 CET.
La empresa informó que estará disponible para reuniones individuales con inversores durante la conferencia (del 3 al 5 de noviembre de 2025) y que información adicional está disponible a través del sitio web de la empresa o por correo electrónico a info@fibrobiologics.com. FibroBiologics se centra en terapias que utilizan fibroblastos y materiales derivados de fibroblastos y posee más de 270 patentes concedidas y pendientes.
FibroBiologics (나스닥: FBLG)가 창립자 겸 CEO인 Pete O’Heren이 Bio-Europe 2025에서 오스트리아 빈에서 발표할 것이라고 발표했습니다, 2025년 11월 4일 CET 기준 오후 4시 15분.
회사에 따르면 컨퍼런스 기간(2025년 11월 3–5일) 동안 일대일 투자자 미팅이 가능하며, 추가 정보는 회사 웹사이트나 info@fibrobiologics.com으로 이메일로 확인할 수 있습니다. FibroBiologics는 섬유아세포 및 섬유아세포 유래 재료를 사용하는 치료법에 집중하며 270건 이상의 특허가 발급되었거나 출원 중입니다.
FibroBiologics (Nasdaq : FBLG) a annoncé que le fondateur et PDG Pete O’Heeron interviendra à Bio-Europe 2025 à Vienne, en Autriche, le 4 novembre 2025 à 16 h 15 CET.
La société a indiqué qu’elle sera disponible pour des réunions privées avec les investisseurs pendant la conférence (du 3 au 5 novembre 2025) et que des informations complémentaires sont disponibles via le site web de l’entreprise ou par courriel à info@fibrobiologics.com. FibroBiologics se concentre sur des thérapeutiques utilisant des fibroblastes et des matériaux dérivés de fibroblastes et détient plus de 270 brevets délivrés et en instance.
FibroBiologics (Nasdaq: FBLG) gab bekannt, dass Gründer und CEO Pete O’Heeron auf der Bio-Europe 2025 in Wien, Österreich, am 4. November 2025 um 16:15 Uhr MEZ auftreten wird.
Das Unternehmen erklärte, dass es während der Konferenz (3.–5. November 2025) persönliche Investorenmeetings anbieten wird und dass weitere Informationen über die Unternehmenswebsite oder per E-Mail an info@fibrobiologics.com verfügbar sind. FibroBiologics konzentriert sich auf Therapeutika, die Fibroblasten und fibroblastenbasierte Materialien verwenden, und hält über 270 patentierte bzw. anhängige Patente.
FibroBiologics (ناسداك: FBLG) أعلن المؤسس والرئيس التنفيذي Pete O’Heeron أنه سيلقي عرضاً في Bio-Europe 2025 في فيينا، النمسا، في 4 نوفمبر 2025 الساعة 4:15 مساءً بتوقيت وسط أوروبا.
وقالت الشركة إنها ستتاح لها لقاءات فردية مع المستثمرين خلال المؤتمر (3–5 نوفمبر 2025) وأن معلومات إضافية متاحة عبر موقع الشركة الإلكتروني أو البريد الإلكتروني info@fibrobiologics.com. تركّز FibroBiologics على العلاجات التي تستخدم fibroblasts والمواد المستمدة من fibroblasts وتمتلك أكثر من 270 براءة اختراع مُصدَرة ومودَعة.
- None.
- None.
HOUSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Bio-Europe 2025 conference taking place November 3-5, 2025, at the Vienna Congress and Convention Center in Vienna, Austria.
FibroBiologics will deliver a company presentation at 4:15 p.m. CET on Tuesday, November 4, and will be available for one-on-one investor meetings throughout the event.
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When will FibroBiologics (FBLG) present at Bio-Europe 2025?
Where is the Bio-Europe 2025 presentation by FibroBiologics (FBLG) taking place?
Who from FibroBiologics (FBLG) will present at Bio-Europe 2025?
Can investors meet FibroBiologics (FBLG) executives at Bio-Europe 2025?
How can I get more information about FibroBiologics (FBLG) at Bio-Europe 2025?
What is FibroBiologics’ (FBLG) area of focus mentioned for the Bio-Europe 2025 presentation?
